Aarti Pharmalabs Shares Surge 20% After Q1 Net Profit Soars 65% YoY to ₹76 Crore.
Aarti Pharmalabs has demonstrated a robust performance in its recent June-quarter results, significantly influencing market reactions as its shares surged to the upper circuit limit of 20% at Rs 823 on the BSE. This rally was fueled by impressive year-on-year growth metrics, with consolidated revenue from operations reaching Rs 535.79 crore, a remarkable increase of 38.7% compared to Rs 386.19 crore during the same quarter last year. The company also reported a consolidated net profit after tax (PAT) of Rs 76.14 crore, reflecting a substantial 65.4% rise from Rs 46.03 crore in Q1 FY26. This strong profit growth was complemented by a notable turnaround from its joint venture, Ganesh Polychem Limited, contributing positively to the bottom line.
Aarti Pharmalabs has also outlined a strategic capital expenditure plan amounting to Rs 149 crore for the establishment of a new Intermediate Block, aimed at enhancing its manufacturing capacity by 405 KL. This investment targets the burgeoning demand from contract development and manufacturing organization (CDMO) partners. The construction of this facility is projected to be completed within a year and will be financed through a combination of internal accruals and borrowings. Such expansion efforts indicate a proactive approach to positioning the company favorably within the competitive market landscape, thus enhancing its capability to meet future demand.
The company also announced key changes in its leadership structure, with transitions of senior roles scheduled to take effect on October 1, 2026, pending shareholder approval. This includes a shift of Shri Rashesh C. Gogri from Non-Executive Director to Managing Director, alongside Smt. Hetal Gogri Gala moving from Managing Director to Executive Director. Such restructuring within the governance architecture is poised to potentially strengthen strategic decision-making as the company navigates its growth trajectory.
On a standalone basis, Aarti Pharmalabs recorded a revenue of Rs 534.59 crore, marking a 42.4% increase from Rs 375.31 crore in the previous year’s quarter, while standalone net profit surged by 49.3% to Rs 71.31 crore. Following the earnings announcement, the stock exhibited strong bullish momentum, opening at Rs 763 and rallying to the upper circuit limit of Rs 823. This recent performance places the stock in close proximity to its 52-week high of Rs 946.10, indicating a strong investor sentiment and optimism surrounding the company’s future prospects.
Source: The Economic Times
(Expert Note: This report was prepared by the Wealthova team.)